GLOBAL MICROBIAL API MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Microbial API Market, By Host (Mammalian, Bacterial, Fungal), By Type (Antibody, Peptide, Protein, Small Molecule, Vaccine, By Site, In-house, Outsourced), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Recent Developments:

On August 24, 2023, Antheia, Inc., a pharmaceutical ingredient manufacturing company, announced the successful completion of its first 116,000 L manufacturing unit in the U.S. with a commercially relevant fermentation for the manufacturing of active pharmaceutical ingredients (APIs) for producing critical medicines for Antheia's pipeline.
On November 27, 2023, Rusan Pharma Ltd., an India-based pharmaceutical company, announced that it had launched a new microbial and conventional active pharmaceutical ingredient (API) manufacturing facility in Madhya Pradesh, India. The company has invested around US$ 36.1 million in its manufacturing unit.

Global Microbial API Market Report Snapshots